4.7 Article

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

Journal

BIOLOGICAL PSYCHIATRY
Volume 74, Issue 4, Pages 250-256

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2012.06.022

Keywords

Antidepressant; experimental therapeutics; glutamate; ketamine; major depressive disorder; treatment-resistant depression

Funding

  1. Mount Sinai School of Medicine
  2. AstraZeneca
  3. Aspect Medical Systems
  4. Forest Laboratories
  5. Janssen Pharmaceutica
  6. Banner Family Fund
  7. Brain and Behavior Fund
  8. Brown Foundation
  9. Bristol-Myers Squibb
  10. Department of Veterans Affairs
  11. Evotec
  12. Johnson and Johnson
  13. National Institute of Mental Health [5R01MH81870]
  14. Allergan
  15. Cephalon
  16. Corcept
  17. Roche
  18. Takeda
  19. NIH

Ask authors/readers for more resources

Background: Ketamine is reported to have rapid antidepressant effects; however, there is limited understanding of the time-course of ketamine effects beyond a single infusion. A previous report including 10 participants with treatment-resistant major depression (TRD) found that six ketamine infusions resulted in a sustained antidepressant effect. In the current report, we examined the pattern and durability of antidepressant effects of repeated ketamine infusions in a larger sample, inclusive of the original. Methods: Participants with TRD (n = 24) underwent a washout of antidepressant medication followed by a series of up to six IV infusions of ketamine (.5 mg/kg) administered open-label three times weekly over a 12-day period. Participants meeting response criteria were monitored for relapse for up to 83 days from the last infusion. Results: The overall response rate at study end was 70.8%. There was a large mean decrease in Montgomery-Asberg Depression Rating Scale score at 2 hours after the first ketamine infusion (18.9 +/- 6.6, p < .001), and this decrease was largely sustained for the duration of the infusion period. Response at study end was strongly predicted by response at 4 hours (94% sensitive, 71% specific). Among responders, median time to relapse after the last ketamine infusion was 18 days. Conclusions: Ketamine was associated with a rapid antidepressant effect in TRD that was predictive of a sustained effect. Future controlled studies will be required to identify strategies to maintain an antidepressant response among patients who benefit from a course of ketamine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available